S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This Stock Could Go Up 66% or More. (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This Stock Could Go Up 66% or More. (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This Stock Could Go Up 66% or More. (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
This Stock Could Go Up 66% or More. (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

$0.40
+0.02 (+5.30%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.38
$0.40
50-Day Range
$0.38
$0.71
52-Week Range
$0.37
$12.58
Volume
22,279 shs
Average Volume
986,100 shs
Market Capitalization
$4.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Bellerophon Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
403.0% Upside
$2.00 Price Target
Short Interest
Healthy
1.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.48mentions of Bellerophon Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars


BLPH stock logo

About Bellerophon Therapeutics (NASDAQ:BLPH) Stock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

BLPH Price History

BLPH Stock News Headlines

ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
BLPH - Bellerophon Therapeutics, Inc.
The Latest Analyst Ratings for Bellerophon Therapeutics
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free.
H.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)
See More Headlines
Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Company Calendar

Last Earnings
8/14/2023
Today
9/30/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+403.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-19,830,000.00
Pretax Margin
-242.52%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
9,383,000
Market Cap
$4.86 million
Optionable
Not Optionable
Beta
0.64
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report













BLPH Stock - Frequently Asked Questions

Should I buy or sell Bellerophon Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares.
View BLPH analyst ratings
or view top-rated stocks.

What is Bellerophon Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price targets for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 403.0% from the stock's current price.
View analysts price targets for BLPH
or view top-rated stocks among Wall Street analysts.

How have BLPH shares performed in 2023?

Bellerophon Therapeutics' stock was trading at $0.90 at the beginning of the year. Since then, BLPH shares have decreased by 55.8% and is now trading at $0.3976.
View the best growth stocks for 2023 here
.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 197,500 shares, an increase of 59.8% from the August 31st total of 123,600 shares. Based on an average daily volume of 193,800 shares, the short-interest ratio is presently 1.0 days.
View Bellerophon Therapeutics' Short Interest
.

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our BLPH earnings forecast
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

When did Bellerophon Therapeutics' stock split?

Bellerophon Therapeutics's stock reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $0.40.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $4.86 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.

This page (NASDAQ:BLPH) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -